5 Stocks to Watch: Week of 5/4/2026

Happy weekend! Gear up for the week ahead with a high-conviction list of stocks to watch, including:

• Kontoor Brands (NYSE: KTB) — Wrangler and Lee owner boasts 74% return on equity
• Gilead Sciences (GILD) — HIV breakthrough and Arcellx deal fuel upside
• Amneal Pharmaceuticals (AMRX) — Biosimilars boom drives 339% EPS growth
• Levi Strauss (LEVI) — DTC transformation delivers double-digit revenue growth
• Neurocrine Biosciences (NASDAQ: NBIX) — Citi sees 89% upside on this biotech breakout

A note from our sponsors...

1- Gilead Sciences Inc (NASDAQ: GILD)

Gilead Sciences is riding powerful momentum after the FDA granted priority review to its once-daily HIV treatment combining bictegravir and lenacapavir, while its newly completed Arcellx acquisition sets the stage for anito-cel's commercial launch. Ranked #1 in the General Drug Manufacturer industry, this biopharmaceutical leader continues delivering standout execution across its HIV and oncology franchises.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $131.64 — get current quote

Max 1-year forecast: $180.00

Why we're watching:

• Analyst support: Strong Wall Street backing with 9 Strong Buy ratings, 2 Buy ratings, and 2 Hold ratings out of 13 analysts covering the stock. See the ratings
• For example, Needham researcher Joseph Stringer (a top 1% rated analyst) recently reiterated his Buy rating with a $170 price target following the company's strategic portfolio expansion. His target suggests over 30% potential upside in the coming year. 
• Industry ranking context: GILD is currently the #1 highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
• Zen Rating highlights: GILD earns an overall Zen Rating of A, putting it in a class of stocks that have historically returned over 30% annually to investors. 
• Component Grades: The stock excels with A grades in Value and Financials, indicating strong fundamentals and attractive valuation metrics, while maintaining a B grade in Safety and Artificial Intelligence exposure. (See all 7 Zen Component Grades here)

2- Neurocrine Biosciences (NASDAQ: NBIX)

Neurocrine Biosciences is a leader in pharmaceuticals targeting neurological, endocrine, and psychiatric disorders, anchored by its blockbuster tardive dyskinesia franchise. Fresh two-year CRENESSITY data — showing sustained glucocorticoid dose reductions while maintaining androgen control in adults with classic congenital adrenal hyperplasia — is supercharging the bull case heading into Q1 earnings.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $134.00 — get current quote

Max 1-year forecast: $242.00

Why we're watching:

• Analyst support: Strong conviction from Wall Street with 8 Strong Buy ratings, 6 Buy ratings, and 3 Hold ratings among 17 analysts covering the stock. See the ratings
• Let’s look at a few of the ratings. For one, Needham's Ami Fadia (a top 1% rated analyst) reiterated a Buy rating with a $185 price target, representing +40.97% upside potential.
• Citigroup's Yigal Nochomovitz (a top 9% rated analyst) maintains the highest price target at $242, representing an impressive +84.41% upside potential.
• Industry ranking context: NBIX is currently the 8th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A. (See what ranks higher here.)
• Zen Rating highlights: TEVA earns an overall A or Strong Buy rating, indicating that it has a higher chance of outperformance than 95% of the stocks in our system.
• Component Grades: NBIX demonstrates outstanding fundamentals with top-tier A grades in both Value and Financials, supported by solid B grades in Growth and AI — positioning it as a high-quality, deeply undervalued pharmaceutical growth story, though investors should note softer Momentum, Sentiment, and Safety scores. See all 7 Zen Component Grades here

A note from our sponsors...

An urgent warning for all U.S. Investors...

"Will You Be On The Right Side Of the Great AI Divide?"

Legendary investment strategist from America's oldest and largest private investment research club bought (split-adjusted) Apple at $1... Netflix at $1.62... Amazon under $2.

Now he's speaking out about 3 AI super-cycle stocks that could dominate the markets.

GET THE FULL STORY HERE

3- Kontoor Brands (NYSE: KTB)

Kontoor Brands is the apparel giant behind the iconic Wrangler and Lee labels, distributing across global markets. A bold new partnership with Chaco for an adventure-ready apparel and footwear line is expanding its reach — all while the company flexes a jaw-dropping 74% return on equity.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $73.36 — get current quote

Max 1-year forecast: $131.00

Why we're watching:

• Analyst support: Strong bullish consensus with 6 Strong Buy ratings and 1 Hold rating from 7 analysts covering the stock. See the ratings
• Wells Fargo's Ike Boruchow (a top 6% rated analyst) maintains a Strong Buy rating with a $100 price target, citing solid sales growth forecast and resilient market fundamentals.
• BTIG's Robert Drbul (a top 12% rated analyst) maintains a Strong Buy rating with a $100 price target, expressing confidence in the growth trajectory reinforced through strategic initiatives including investment in technology.
• Industry ranking context: KTB is currently the 3rd highest-rated stock in the Apparel Manufacturing industry, which has an Industry Rating of A.
• Zen Rating highlights: KTB ranks in the top 5% of stocks we track based on a rigorous 115-factor review. (It’s better-rated than even NVDA!)
• Component Grades: KTB excels with an A-rated Value component, complemented by B grades in Growth and Financials, while the company's 30.96% earnings growth significantly outpaces the market average. See all 7 Zen Component Grades here

4- Levi Strauss & Co (NYSE: LEVI)

Levi Strauss, the iconic denim brand, is pulling off a stunning transformation into a DTC-first lifestyle powerhouse — and the numbers prove it. Q1 2026 direct-to-consumer revenues surged 16% year-over-year and now account for more than half of total revenue, with heritage demand and sharp operational focus fueling the fastest, most consistent growth in the company's history.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $22.28 — get current quote

Max 1-year forecast: $34.00

Why we're watching:

• Analyst support: Strong consensus with 2 Strong Buy ratings and 3 Buy ratings from 5 analysts covering the stock, with zero Hold, Sell, or Strong Sell ratings. See the ratings
• For example, UBS researcher Jay Sole (a top 7% rated analyst) recently raised his price target to $34 following Q1 earnings, noting the company is "undertaking a transformation into a global, multi-channel, lifestyle brand for both men and women" that will support mid-single-digit revenue growth with mid-teens margins over time.
• Recent catalysts: Q1 2026 earnings showcased exceptional execution with EPS of $0.42 beating estimates by 13.51% and revenue of $1.74B exceeding expectations by 5.45%, both growing double-digits year-over-year as the DTC transformation gains momentum.
• Industry ranking context: LEVI is currently the #1 highest-rated stock in the Apparel Manufacturing industry, which has an Industry Rating of A.
• Zen Rating highlights: As an A or Strong Buy rated stock, LEVI ranks in the top 5% of stocks we track based on a 115-factor evaluation of factors that have historically driven long-term stock growth. 
• Component Grades: Well-rounded performance with A grade in Sentiment reflecting strong analyst confidence, B grades in Value, Growth, Safety, and Financials, demonstrating solid fundamentals across the board. (See all 7 Zen Component Grades here)

5- Amneal Pharmaceuticals Inc (NASDAQ: AMRX)

Amneal Pharmaceuticals is emerging as a powerhouse in biosimilars scale opportunities, with strong preliminary Q1 results and a game-changing Kashiv BioSciences acquisition igniting analyst enthusiasm. Now ranked #1 in the Pharmaceutical industry, this generic and specialty drug manufacturer is positioned for serious upside.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $12.80 — get current quote

Max 1-year forecast: $19.00

Why we're watching:

• Analyst support: AMRX enjoys unanimous bullish sentiment with 4 out of 4 analysts rating the stock Strong Buy. See the ratings
• For example, UBS researcher Ashwani Verma (a top 14% rated analyst) recently initiated coverage with a Strong Buy rating and $19 price target, representing 48% upside potential, highlighting the company's biosimilar pipeline and anticipated 2026-2027 upside from biosimilars scale.
• AMRX also enjoys strong support from our Editor-in-Chief Steve Reitmeister, whose recent video showcases the stock’s strengths. Watch it here
• Great growth: The company's earnings growth of 128.71% significantly outpaces both the industry average of 19.9% and market average of 72.31%, with EPS forecasted to grow from $0.23 to $1.01 over the next year—a remarkable 339% increase.
• Industry ranking context: AMRX is currently the #1 highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — AMRX is in the top echelon of stocks we track.
• Component Grades: Outstanding performance in Growth (A) and Sentiment (A) grades, reflecting strong analyst conviction and impressive earnings expansion potential, complemented by a solid B grade in Value. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.